Epsilogen is a global leader in the development of immunoglobulin (IgE) antibodies to treat cancer. IgE has several key features that make it ideal for the treatment of solid tumours including greater potency, enhanced tumour access and a long tissue half-life. The company's lead programme targets the folate receptor alpha (FR alpha) and an anti-FR alpha IgE antibody is currently in a phase I trial to treat ovarian cancer. This is the world's first IgE therapeutic to enter the clinic.
| Website | https://epsilogen.com/ |
| Revenue | $6.9 million |
| Employees | 33 (21 on RocketReach) |
| Founded | 2016 |
| Phone | +44 20 3657 7612 |
| Industry | Biotechnology, Pharmaceuticals, Healthcare |
| Keywords | Cancer Treatment, Solid Tumor Treatment, Cancer Immunotherapy, Antibody Therapeutics, Oncology Therapeutics, Immunotherapy, Therapeutic Antibodies, Monoclonal Antibodies, Immuno-Oncology, Biopharmaceutical, Pharmaceutical Research, Targeted Therapy, Drug Development, Biotechnology, Novel Therapeutics, Protein Therapeutics, Clinical Stage |
| Competitors | Johnson & Johnson, Roche, Novartis, Merck & Co., Inc., GSK, AstraZeneca, Genentech, Amgen, Regeneron, Biogen +43 more (view full list) |
| SIC | SIC Code 283 Companies, SIC Code 80 Companies, SIC Code 28 Companies |
| NAICS | NAICS Code 32 Companies, NAICS Code 325 Companies, NAICS Code 3254 Companies |
Looking for a particular Epsilogen Ltd employee's phone or email?
Epsilogen Ltd Questions
The Epsilogen Ltd annual revenue was $6.9 million in 2026.
Nick Robbins-Cherry is the CFO of Epsilogen Ltd.
21 people are employed at Epsilogen Ltd.
The NAICS codes for Epsilogen Ltd are [32, 325, 3254].
The SIC codes for Epsilogen Ltd are [283, 80, 28].
Top Epsilogen Ltd Employees
-
24
-
22
-
22
-
Ashley Nagle
Chief Business Officer at Epsilogen Ltd
Strasbourg, FR2 -
James Birtley
Principal Scientist at Epsilogen Ltd
United Kingdom24 -
32
-
2
-
1
-
John Devlin
Senior Scientist at Epsilogen Ltd
United Kingdom1
Related Companies
